MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • 2016 International Congress

    Prevalence of orthostatic hypotension after a low subacute levodopa dose in patients with parkinsonism

    G. Calandra-Buonaura, L. Sambati, I. Gessaroli, A. Turrini, R. Terlizzi, G. Giannini, P. Guaraldi, P. Cortelli (Bologna, Italy)

    Objective: To evaluate the prevalence of orthostatic hypotension (OH) after a low subacute levodopa (LD) dose in patients with diagnosis of Parkinson's disease (PD) or…
  • 2016 International Congress

    Therapy escalation in Parkinson’s disease – The TEMP trial, a regional survey

    F. Gandor, A. Kühn, J. Müller, F. Klostermann, T. Müller, D. Gruber, A. Lipp, A. Kivi, D. Kübler, F. Ehlen, G. Ebersbach (Beelitz-Heilstätten, Germany)

    Objective: To assess socio-demographic and disease specific data in patients with Parkinson's disease (PD) before and one year after therapy escalation with subcutaneous apomorphine (APO),…
  • 2016 International Congress

    Levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients: Final long-term non-motor, quality of life and safety results from the GLORIA registry

    K.R. Chaudhuri, Z. Pirtosek, B. Pickut, W. Poewe, F. Valldeoriola, L. Defebvre, R. Jech, P. Odin, C. Winkler, J. Szasz, K. Onuk, A. Yegin, L. Bergmann, A. Antonini (London, United Kingdom)

    Objective: To evaluate the tolerability and effect of levodopa-carbidopa intestinal gel (LCIG, designated in the US as carbidopa-levodopa enteral suspension) on non-motor symptoms (NMS), quality…
  • 2016 International Congress

    Preliminary results of a cross-linguistic comparison on dysarthria in Parkinson’s disease

    J. Sadat, R. Cardoso, H. Santos, J. Carvalho, I. Guimarães, F. Viallet, J.J. Ferreira, S. Pinto (Aix-en-Provence, France)

    Objective: To evaluate the effects of language, disease duration, and medication on acoustic and prosodic parameters in the speech of Parkinson's disease (PD) patients. Background:…
  • 2016 International Congress

    MEK inhibitors have antidyskinetic effects in hemiParkinsonian rats that are associated with critical neurochemical alterations in the striatum

    G. Chen, S. Nie, K. Ma, C. Han, Y. Xu, Z. Zhang, S.M. Papa, X. Cao (Wuhan, People's Republic of China)

    Objective: To examine the effects of MEK inhibitors PD98059 and U0126 on L-DOPA-induced dyskinesia and the induced molecular changes. Background: L-DOPA-induced dyskinesia (LID) represents one…
  • 2016 International Congress

    Dopaminergic medicines are alternative drugs for treatment of motor disorders in ischemic stroke

    A. Azimov, R. Sadykov, G. Rakhimbaeva, S. Dadajonov, O. Azizova (Tashkent, Uzbekistan)

    Objective: To study the possibility of using levodopa and amantadine for the treatment of motor disorders in ischemic stroke after taking the standard treatment. Background:…
  • 2016 International Congress

    Experience with utilization of rytary in the clinical setting

    Y. Kianirad, T. Simuni, C. Zadikoff, D. Bega, M. Afshari, S. Jonnalagadda (Chicago, IL, USA)

    Objective: To explore the utilization and tolerability of Rytary in the clinical setting. Background: Rytary is a novel extended-release carbidopa-levodopa (CD-LD) formulation that was approved…
  • 2016 International Congress

    The effect of levodopa-carbidopa intestinal gel on activities of daily living: Results from the observational MONOTREAT study in advanced Parkinson’s disease patients

    R. Krüger, P. Lingor, T. Doskas, J. Henselmans, E.H. Danielsen, O. de Fabregues, A. Stefani, S.C. Sensken, J.C. Parra Riaza, K. Onuk, A. Yegin (Tübingen, Germany)

    Objective: To assess the tolerability and effect of levodopa-carbidopa intestinal gel (LCIG, designated in the United States as carbidopa-levodopa enteral suspension) on activities of daily…
  • 2016 International Congress

    Comorbid conditions associated with Parkinson´s disease: A longitudinal study

    D. Santos García, E. Suarez Castro, I. Expósito, T. de Deus, C. Tuñas, D. Núñez Arias, Á. Aneiros, M. López Fernández, J. Naveiro, J. Abella, M.A. Llaneza, V. Vilas, M. Macías (Ferrol, Spain)

    Objective: (1)To study what comorbid conditions were present at baseline and 3 years later in a cohort of Spanish PD patients and (2) to analyze…
  • 2016 International Congress

    Selective M4 antagonism potentiates L-DOPA-induced dyskinesia in MPTP-treated common marmosets

    D. Klisko, R. Fisher, L. Lincoln, P. Jenner, S. Rose (London, United Kingdom)

    Objective: To determine the role of M4 muscarinic receptors in the expression of L-DOPA-induced dyskinesia (LID) and dystonia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated common marmosets. Background:…
  • « Previous Page
  • 1
  • …
  • 49
  • 50
  • 51
  • 52
  • 53
  • …
  • 57
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • “Striatal Hand Signs” and early diagnosis of Parkinson's Disease: The “Monkey-Wrench Sign”.
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • An atypical and interesting feature of Parkinson´s disease
  • Patients with Essential Tremor Live Longer than their Relatives
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley